Clear Cell Ependymoma Terminated Phase 1 Trials for Vitespen (DB06400)

IndicationStatusPhase
DBCOND0086684 (Clear Cell Ependymoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02722512Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) VaccineTreatment